Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1

Trial Profile

An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Feb 2019

At a glance

  • Drugs IPN 01087 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Ewing's sarcoma; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Ipsen
  • Most Recent Events

    • 29 Nov 2018 Planned number of patients changed from 300 to 320.
    • 29 Nov 2018 Planned End Date changed from 22 Nov 2021 to 28 Mar 2022.
    • 29 Nov 2018 Planned primary completion date changed from 27 Sep 2021 to 7 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top